Themis Bioscience was established in 2009 by a team of seasoned biotech professionals with leading immunology expertise and an unparalleled network of academic immunologists and vaccine specialists. Only a year after its foundation, Themis signed a joint research and development agreement with the Institut Pasteur, a world-leading European vaccine research institute. This highly prestigious partnership gave Themis rights on an innovative measles virus vaccine vector technology that now forms the basis of our platform technology. Themis is supported by a consortium of experienced life science investors including Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences and a scientific advisory board of leading experts in the field of vaccine technology and immunology.